Jae Park, MD, wraps up his discussion by highlighting exciting investigational agents on the horizon for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.
Dr Jae Park shares his experience with using brexucabtagene autoleucel for patients with relapsed/refractory B-cell acute lymphoblastic leukemia in clinical practice since its FDA approval in October 2021.
Jae Park, MD, explains how real-world CAR T-cell therapy data in patients with relapsed/refractory B-cell acute lymphoblastic leukemia shows high response rates but emphasizes the ongoing need for optimizing toxicity management, with trends toward earlier treatment and cell collection.
Dr Jae Park details the treatment options for relapsed/refractory B-cell acute lymphoblastic leukemia, including blinatumomab, inotuzumab ozogamicin, and CAR T-cell therapy, with the treatment choice dependent on patient factors like comorbidities, disease burden, and transplant status.
When one thinks about military drones they tend to image the largest of them, things like the RQ-4 Global Hawk or the MQ-1 Predator. These are also some .